Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
DNLI
Home
/
DNLI

NASDAQ
$20.96
$20.96

Overview

Price performance
Low
$19.75
High
$22.19
Market closed. Last updated: Nov 4, 2026, 9:00 PM UTC
$
20.96
1.51 (7.76%)
Average, 50 days
$20.43
$21.24
Open
$21.23
Previous close
$19.45
52-week high
$27.30
Jul 9, 2026 (4 months ago)
52-week low
$13.75
Nov 7, 2025 (13 months ago)
52.44%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
3.35B
Volume
4 648 983
Total Return (3M)
-13.28%
Total Return (1Y)
40.48%
3135.85
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
US
Website
denalitherapeutics.com
About
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.

Frequently asked questions

DNLI · Denali Therapeutics Inc.

01What is Denali Therapeutics Inc. stock price today?

The current price of DNLI is $20.96 — it has increased by 7.76% since the previous close. Data as of Nov 4, 2026.

02Is Denali Therapeutics Inc. stock price growing?

DNLI is up 8.88% over the past week, up 4.80% over the past month and up 40.48% over the past year. The price is below its 200-day moving average of $21.24.

03What is DNLI stock forecast?

Analysts' average 12-month price target for DNLI is $33.67, which implies 60.64% upside from the current price. Individual estimates range from $26.00 to $41.00.

04What do analysts say about DNLI stock?

Of the 20 analysts covering Denali Therapeutics Inc., 2 rate it a strong buy, 17 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

05What is Denali Therapeutics Inc. market cap?

Denali Therapeutics Inc. has a market capitalization of $3.35B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

06What were Denali Therapeutics Inc. earnings last quarter?

In its most recent quarterly report, Denali Therapeutics Inc. posted earnings of $0.37 per share against an estimate of -$0.3222, beating expectations by 214.84%. Upcoming reports are listed in the earnings calendar.

07What is Denali Therapeutics Inc. revenue for the last quarter?

Denali Therapeutics Inc. reported revenue of $17.78M in its most recent quarter. Analysts had expected $12.22M.

08Does Denali Therapeutics Inc. pay dividends?

Denali Therapeutics Inc. has not paid any dividends over the past year.

09Who are Denali Therapeutics Inc. competitors?

Companies most comparable to Denali Therapeutics Inc. include Neurocrine Biosciences, Inc., Praxis Precision Medicines, Inc., Ionis Pharmaceuticals, Inc., Amylyx Pharmaceuticals, Inc. and Biohaven Ltd.

10How volatile is DNLI stock?

In the latest trading session DNLI moved between $19.75 and $22.19, a range of 11.64% of its current price.

11Should I invest in Denali Therapeutics Inc. stock?

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Denali Therapeutics Inc. shows a strong buy rating today and a neutral rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Denali Therapeutics Inc. is neutral. Technical ratings are indicators, not investment advice.

12What are DNLI stock 52-week high and low?

Over the past 52 weeks DNLI has traded between $13.75 and $27.30. The current price is 23.22% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.